You can help.
The National Leiomyosarcoma Foundation ( NLMSF TEAM) embraces a dedicated and committed volunteer community of active LMS patients/survivors, caregivers, families, friends, co-workers, advocates/supporters – who all contribute to the mission and purpose of the Foundation. We encourage you to join the NLMSF TEAM – join us and bring your ideas, creativity, commitment and enthusiasm to help make a difference for the LMS Community – “Many hands make light work for small projects.”Contact Annie Achee at 303 808-3437 to volunteer. We would love to have you with us! We are a caring, genuine, group that only wants to do the best for patients and their families. Together we make an impact for the better!
Ways to Get Involved:
- ATTEND PATIENT EDUCATION PROGRAMS – held throughout the year. Check Patient Education page for calendar updates.
- BE A VOLUNTEER FOUNDATION AMBASSADOR – Help the Foundation with a small project. Initiate a project you feel passionate about doing, based on your time / availability. The Foundation has at least 50 fundraising ideas to share. Students and young professionals can also be Ambassadors to help raise awareness and LMS research funding.
- THINK OF A PROJECT AT CHURCH, SCHOOL, WORK, CLUB AFFILIATION, in connection with a holiday to make it a festive fundraising effort. Fall is a great time to launch a fundraising project.JULY 15 IS LMS AWARENESS DAY – A fundraising event on this day would highlight awareness of LMS. Contact Annie at 303 783-0924 or email at: firstname.lastname@example.org for the Ideas List to share with you.* BE A FACEBOOK/TWITTER PARTICIPANT – Connect with patients/supporters/Foundation board members. See information updates posted about research articles/news/updates.* CONTRIBUTE – Invest in the future of surviving LMS. It is all about the present and the future of Leiomyosarcoma research breakthroughs to advance treatment options and extend survival for patients.
Invest in Research Breakthroughs To Advance Treatment:
It is easy to make a contribution to research in honor/ tribute for someone who has been a special part of your life.
NLMSF FUNDING SUPPORT FOR RESEARCH PROJECTS – Through “investing” in LMS Research, patients, families, friends came together to support /contribute to the Foundation ’s funding of important LMS research projects. All donations are investment “gifts” directed to LMS research – lighting the way to the discovery that can turn into clinical care treatment options . . . “gifts” that keep on giving!
YOUR DOLLARS IN ACTION:
- The Foundation supports the new research initiative for the P53 – the study of potentially targetable mutations – p53, with 10 additional elements that can be applied to LMS. The role of macrophages in tumor microenvironment for LMS – Anti-PD1 investigational research, comparing macrophages in LMS vs breast and colon cancer is beginning. Development of new antibody vs macrophage in combination with anti-PD-1 antibody is being investigated (Pembrolizumab and Optivo); validation of LMS cell lines and PDX models and SARC trial patients to search for targeted tumor signatures; identification of such tumor search signatures will benefit P13/mTOR, p53, LGF1R, ER therapies.
- The Specialized Program of Research Excellence (SPORE), a Sarcoma Alliance Through Research and Collaboration research project for new biologically-rational clinical trials in sarcoma, that hold promise for cross over progress in a variety of sarcoma subtypes, including LMS.
- Development of a non-invasive diagnostic assay for highly accurate pre-operative distinction between uterine leiomyomas and leiomyosarcomas. The detection of circulating tumor
DNA, reported in several cancers, but only a few in sarcomas and no large-scale study to detect ctDNA for LMS patients –inspired further study for sarcomas and brought a proof of principle study to include LMS patients to determine the feasibility of ctDNA analysis. Such an analysis would enable clinicians to identify patients who could safely undergo laparoscopic procedures using power morcellators. A “liquid biopsy” test based on the analysis of tumor-associated genetic aberrations in circulating tumor DNA (ctDNA) in plasma may be of great use such situations.